These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

619 related items for PubMed ID: 27008031

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].
    Warnke C, Adams O, Hartung HP, Gold R, Hemmer B, Hohlfeld R, Stangel M, Zipp F, Wiendl H, Kieseier BC.
    Nervenarzt; 2011 Oct; 82(10):1314-9. PubMed ID: 21656322
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, López de Munain A, Olascoaga J, Baranzini SE, Otaegui D.
    Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
    [Abstract] [Full Text] [Related]

  • 28. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
    Piu C, Ibba G, Bertoli D, Capra R, Uleri E, Serra C, Imberti L, Dolei A.
    J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
    [Abstract] [Full Text] [Related]

  • 29. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
    Boziki MK, Karapanayotides T, Papadopoulos G, Lagoudaki R, Melo P, Bakirtzis C, Nikolaidis I, Gounari E, Tsavdaridou V, Skoura L, Afrantou T, Tatsi T, Grigoriadou E, Polyzoidou E, Mandoras N, Giantzi V, Kalogera-Fountzila A, Ioannidis P, Parissis D, Pelidou SH, Zoidou S, Grigoriadis N.
    Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
    [Abstract] [Full Text] [Related]

  • 30. Natalizumab treatment of multiple sclerosis: new insights.
    Delbue S, Comar M, Ferrante P.
    Immunotherapy; 2017 Jan; 9(2):157-171. PubMed ID: 28004598
    [Abstract] [Full Text] [Related]

  • 31. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    Skarlis C, Papadopoulos V, Raftopoulou S, Mavragani CP, Evangelopoulos ME.
    J Neurol Sci; 2024 Jun 15; 461():123046. PubMed ID: 38761670
    [Abstract] [Full Text] [Related]

  • 32. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
    Miranda Acuña JA, Weinstock-Guttman B.
    Mult Scler Relat Disord; 2016 Sep 15; 9():54-5. PubMed ID: 27645344
    [Abstract] [Full Text] [Related]

  • 33. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
    Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, Ryschkewitsch C, Jensen P, Lippmann K, Hemmer B, Major E, Hohlfeld R.
    Mult Scler; 2013 Aug 15; 19(9):1213-5. PubMed ID: 23124790
    [Abstract] [Full Text] [Related]

  • 34. Use of natalizumab in persons with multiple sclerosis: 2022 update.
    Morrow SA, Clift F, Devonshire V, Lapointe E, Schneider R, Stefanelli M, Vosoughi R.
    Mult Scler Relat Disord; 2022 Sep 15; 65():103995. PubMed ID: 35810718
    [Abstract] [Full Text] [Related]

  • 35. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR, Scarpazza C, Cordioli C, De Rossi N, Rasia S, Turrini MV, Capra R.
    Mult Scler; 2021 Apr 15; 27(5):790-794. PubMed ID: 32749910
    [Abstract] [Full Text] [Related]

  • 36. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
    Werner MH, Huang D.
    J Neurovirol; 2016 Dec 15; 22(6):871-875. PubMed ID: 27198748
    [Abstract] [Full Text] [Related]

  • 37. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
    Uleri E, Ibba G, Piu C, Caocci M, Leoni S, Arru G, Serra C, Sechi G, Dolei A.
    J Neurovirol; 2017 Apr 15; 23(2):226-238. PubMed ID: 27812788
    [Abstract] [Full Text] [Related]

  • 38. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I.
    Lancet Neurol; 2017 Nov 15; 16(11):925-933. PubMed ID: 28969984
    [Abstract] [Full Text] [Related]

  • 39. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
    D'Amico E, Zanghì A, Leone C, Tumani H, Patti F.
    Drug Saf; 2016 Dec 15; 39(12):1163-1174. PubMed ID: 27696299
    [Abstract] [Full Text] [Related]

  • 40. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.
    McCormack PL.
    Drugs; 2013 Sep 15; 73(13):1463-81. PubMed ID: 23912625
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.